Toggle Main Menu Toggle Search

Open Access padlockePrints

Targeting CD19 with genetically modified EBV-specific human T lymphocytes

Lookup NU author(s): Professor Hermann Josef Vormoor


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Human Epstein-Barr virus-specific T cells were genetically modified to express chimeric receptors specific for human CD19, which is expressed on the cell surface of most B cell malignancies. The receptor-modified EBV-specific T cells can be expanded and maintained long term in the presence of EBV-infected B cells. They recognize autologous EBV-infected targets through their conventional T cell receptor, and allogeneic EBV-infected targets and tumor targets through their chimeric receptor. They efficiently lyse both EBV and CD19-positive tumor targets in the absence of background cytotoxicity against CD19-negative targets. Donor-derived EBV-specific T cells expressing chimeric anti-tumor receptors may represent a source of effector cells that could be safely administered to leukemia patients to eradicate minimal residual disease after allogeneic bone marrow transplantation.

Publication metadata

Author(s): Roessig C, Scherer SP, Baer A, Vormoor J, Rooney CM, Brenner MK, Juergens H

Publication type: Article

Publication status: Published

Journal: Annals of Hematology

Year: 2002

Volume: 81

Issue: Suppl. 2

Pages: S42-S43

Print publication date: 01/09/2002

ISSN (print): 0939-5555

ISSN (electronic): 1432-0584

Notes: Conference: Third International Symposium TRANSPLANTATION IN HEMATOLOGY AND ONCOLOGY, Stem cells potential, cellular therapy, clinical perspectives. September 6 and 7, 2002, M√ľnster, Germany.